| Autor: |
Ramalingam, Sakkaraiappan, Dobbs, Tracy W., Einzig, Avi I., Wojtowicz-Praga, Slawomir, Cascino, Marianne, Bonomi, Phillip, Belani, Chandra P. |
| Předmět: |
|
| Zdroj: |
Cancer Chemotherapy & Pharmacology; May2004, Vol. 53 Issue 5, p439-444, 6p |
| Abstrakt: |
Background. To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer. Methods. In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml·min and docetaxel 80 mg/m2 administered once every 3 weeks. Results. A total of 45 patients were accrued to the study. The median age was 62 years and adenocarcinoma was the most common histology. Patients received a median of four cycles of chemotherapy. The objective response rate was 29% with a median survival of 11.9 months among evaluable patients. The 1-year survival rate was 47%. Febrile neutropenia (17%) was the most common hematological toxicity associated with the regimen whereas grade 3 fatigue (4%) was the major nonhematological toxicity. Conclusions. The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink